Anagrelide Hydrochloride Hydrate

盐酸阿那格雷

Report date: 2026/03/16 20:01:47
NME

Base Information

Drug NameAnagrelide Hydrochloride Hydrate
Drug Alias NameAgrelid阿那格雷水合盐酸阿那格雷Anagrelide hydrochlorideAnagrelidum +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 3 inhibitors
TargetsPhosphodiesterase 3
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocytosis +[6] 
Global Approved IndicationsMyeloproliferative DisordersThrombocythemia, Essential
Approved Indications in ChinaThrombocythemia, Essential
Original Approved Country/TerritoryUnited States
Original Approved Date1997/03/14
Country/TerritoryBulgariaUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncTakeda Pharmaceuticals International AG Ireland BranchTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesShireMylan Pharmaceuticals IncAop Orphan Pharmaceuticals Ag +[5] 
Active IndicationsMyeloproliferative DisordersThrombocythemia, Essential
Inactive IndicationsPrimary MyelofibrosisThrombocytosisPolycythemia Vera +[4] 

Other Information

ATC CodeL01XX35
Related LinksWikipediaDrugBankKEGG